Celtaxsys, a clinical-stage pharmaceutical development company, has indicated clinically meaningful improvements in pulmonary exacerbations in the phase two Empire- cystic fibrosis trial of Acebilustat, it was reported on Friday.
Acebilustat is a small molecule inhibitor of Leukotriene A4 Hydrolase, the crucial enzyme in the production of the potent inflammatory mediator Leukotriene B4. It has decreased the frequency of pulmonary exacerbations and increased the time to next exacerbation over 48 weeks of therapy in the 200-patient, double-blind and placebo controlled study.
Acebilustat-treated patients demonstrated 19% decrease in pulmonary exacerbations and 22% reduced risk in progressing to first pulmonary exacerbations against placebo, on a per protocol assessment. The once-daily oral drug candidate is advancing to phase three development. It was designed to modulate the neutrophil driven immune response and bring the inflammation to homeostasis, allowing to avoid overactive inflammation.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera